Crizotinib Effective for NSCLC Brain Metastases

Share this content:
Crizotinib demonstrated a significantly higher intracranial disease control rate and prolonged progression-free survival in patients with treated brain metastases.
Crizotinib demonstrated a significantly higher intracranial disease control rate and prolonged progression-free survival in patients with treated brain metastases.

Crizotinib demonstrated a significantly higher intracranial disease control rate and prolonged progression-free survival as compared with chemotherapy in patients with treated brain metastases, a study published in the Journal of Clinical Oncology has shown.1

Previous studies have demonstrated that crizotinib, a kinase inhibitor, is effective for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive. In this study, researchers sought to evaluate the intracranial efficacy of first-line crizotinib vs chemotherapy.

For the phase 3 trial, researchers enrolled 343 patients with ALK-positive NSCLC, of which 23% had stable treated brain metastases at baseline. Patients were randomly assigned 1:1 to receive crizotinib 250 mg orally twice daily, or pemetrexed 500 mg/m2 IV plus either cisplatin 75 mg/m2 or carboplatin AUC 5-6 IV every 3 weeks for no more than 6 cycles.

Researchers assessed intracranial efficacy at baseline and every 6 or 12 weeks in patients with or without known brain metastases, respectively.

Results showed that there was a nonsignificant improvement in intracranial time to progression with crizotinib in the intent-to-treat population of 363 patients (HR, 0.60; P = .069), patients with treated brain metastases (HR, 0.45; P = .063), and patients without brain metastases (HR, 0.69; P = .323).

The authors noted that although the improvement in intracranial time to progression was not statistically significant in either subgroup, sensitivity to detect treatment differences in or between the 2 subgroups was low.

However, researchers observed a significantly higher intracranial disease control rate with crizotinib vs chemotherapy at 12 weeks (85% vs 45%; P < .001) and 24 weeks (56% vs 25%; P = .006) among patients with treated brain metastases.

RELATED: Negative Low-dose CT Prevalence Screening Linked With Lower Lung Cancer-specific Mortality

Researchers found that progression-free survival was also significantly longer crizotinib as compared with chemotherapy in both patients with treated brain metastases (HR, 0.40; P < .001) and those without brain metastases (HR, 0.51; P < .001), as well as patients in the intent-to-treat population (HR, 0.45; P < .001).

Reference

  1. Solomon BJ, Cappuzzo F, Felip E, et al. Intracranial efficacy of crizotinib versus chemotherapy in patients with advanced ALK-positive non–small-cell lung cancer: results from PROFILE 1014 [published online ahead of print March 28, 2016]. J Clin Oncol. doi: 10.1200/JCO.2015.63.5888.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs